$INVA News

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors

Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate

Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation

Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals

Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?

INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout

Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform

Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally

Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commercialize XACDURO To Treat Bacterial Pneumonia

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price Target

BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target

INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals

Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?